Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines

Journal of Virological Methods

Volumn 169, Issue 2, 2010, Pages 365-374

  Whitt, Michael A ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Envelope glycoprotein; High throughput screening; Pseudotypes; Receptor identification; Transfection; Vaccines; Virus entry; VSV

Indexed keywords

PLASMID VECTOR; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ARTICLE; CELL SUSPENSION; CULTURE TECHNIQUE; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; METHODOLOGY; NONHUMAN; PHASE CONTRAST MICROSCOPY; PLASMID PURIFICATION; PRIORITY JOURNAL; PSEUDOTYPING; PURIFICATION; TRANSIENT EXPRESSION; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIROGENESIS; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS PLAQUE; VIRUS RECOMBINANT;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; GENE DELETION; HUMANS; MEMBRANE GLYCOPROTEINS; RECOMBINANT PROTEINS; VESICULOVIRUS; VIRAL ENVELOPE PROTEINS; VIRAL LOAD; VIRAL VACCINES; VIRUS CULTIVATION; VIRUS INTERNALIZATION;

ANIMALIA; HEXAPODA; MAMMALIA; VESICULAR STOMATITIS VIRUS;

EID: 77957019441     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2010.08.006     Document Type: Article

References (41)

1. Abe K., Nozaki A., Tamura K., Ikeda M., Naka K., Dansako H., Hoshino H.O., Tanaka K., Kato N. Tandem repeats of lactoferrin-derived anti-hepatitis C virus peptide enhance antiviral activity in cultured human hepatocytes. Microbiol. Immunol. 2007, 51:117-125.
2. Fredericksen B.L., Whitt M.A. Vesicular stomatitis virus glycoprotein mutations that affect membrane fusion activity and abolish virus infectivity. J. Virol. 1995, 69:1435-1443.
3. Fuerst T.R., Niles E.G., Studier R.W., Moss B. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc. Natl. Acad. Sci. U.S.A. 1986, 83:8122-8126.
4. Fukushi S., Mizutani T., Saijo M., Matsuyama S., Miyajima N., Taguchi F., Itamura S., Kurane I., Morikawa S. Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein. J. Gen. Virol. 2005, 86:2269-2274.
5. Fukushi S., Watanabe R., Taguchi F. Pseudotyped vesicular stomatitis virus for analysis of virus entry mediated by SARS coronavirus spike proteins. Methods Mol. Biol. 2008, 454:331-338.
6. Ge J., Wen Z., Wang X., Hu S., Liu Y., Kong X., Chen H., Bu Z. Generating vesicular stomatitis virus pseudotype bearing the severe acute respiratory syndrome coronavirus spike envelope glycoprotein for rapid and safe neutralization test or cell-entry assay. Ann. NY Acad. Sci. 2006, 1081:246-248.
7. Glende J., Schwegmann-Wessels C., Al-Falah M., Pfefferle S., Qu X., Deng H., Drosten C., Naim H.Y., Herrler G. Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2. Virology 2008, 381:215-221.
8. Hanika A., Larisch B., Steinmann E., Schwegmann-Wessels C., Herrler G., Zimmer G. Use of influenza C virus glycoprotein HEF for generation of vesicular stomatitis virus pseudotypes. J. Gen. Virol. 2005, 86:1455-1465.
9. Huang A.S., Palma E.L., Hewlett N., Roizman R. Pseudotype formation between enveloped RNA and DNA viruses. Nature 1974, 252:743-745.
10. Ito H., Watanabe S., Sanchez A., Whitt M.A., Kawaoka Y. Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. J. Virol. 1999, 73:8907-8912.
11. Jayakar H.R., Jeetendra E., Whitt M.A. Rhabdovirus assembly and budding. Virus Res. 2004, 106:117-132.
12. Jayakar H.R., Whitt M.A. Identification of two additional translation products from the matrix (M) gene that contribute to vesicular stomatitis virus cytopathology. J. Virol. 2002, 76:8011-8018.
13. Jeetendra E., Robison C.S., Albritton L.M., Whitt M.A. The membrane-proximal domain of vesicular stomatitis virus G protein functions as a membrane fusion potentiator and can induce hemifusion. J. Virol. 2002, 76:12300-12311.
14. Johnson J.E., Rodgers W., Rose J.K. A plasma membrane localization signal in the HIV-1 envelope cytoplasmic domain prevents localization at sites of vesicular stomatitis virus budding and incorporation into VSV virions. Virology 1998, 251:244-252.
15. Kaariainen L., Gomatos P.J. A kinetic analysis of the synthesis in HK21 cells of RNAs specific for Semliki Forest virus. J. Gen. Virol. 1969, 5:251-265.
16. Kaimori A., Kanto T., Kwang Limn C., Komoda Y., Oki C., Inoue M., Miyatake H., Itose I., Sakakibara M., Yakushijin T., Takehara T., Matsuura Y., Hayashi N. Pseudotype hepatitis C virus enters immature myeloid dendritic cells through the interaction with lectin. Virology 2004, 324:74-83.
17. Klas S.D., Robison C.S., Whitt M.A., Miller M.A. Adjuvanticity of an IL-12 fusion protein expressed by recombinant deltaG-vesicular stomatitis virus. Cell. Immunol. 2002, 218:59-73.
18. Lee B.H., Yoshimatsu K., Araki K., Okumura M., Nakamura I., Arikawa J. A pseudotype vesicular stomatitis virus containing Hantaan virus envelope glycoproteins G1 and G2 as an alternative to hantavirus vaccine in mice. Vaccine 2006, 24:2928-2934.
19. Lefrancois L., Lyles D.S. The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. I: analysis of neutralizing epitopes with monoclonal antibodies. Virology 1982, 121:157-167.
20. Matsuura Y., Tani H., Suzuki K., Kimura-Someya T., Suzuki R., Aizaki H., Ishii K., Moriishi K., Robison C.S., Whitt M.A., Miyamura T. Characterization of pseudotype VSV possessing HCV envelope proteins. Virology 2001, 286:263-275.
21. Miller M.A., Lavine C.L., Klas S.D., Pfeffer L.M., Whitt M.A. Recombinant replication-restricted VSV as an expression vector for murine cytokines. Protein Exp. Purif. 2004, 33:92-103.
22. Mire C.E., Dube D., Delos S.E., White J.M., Whitt M.A. Glycoprotein-dependent acidification of vesicular stomatitis virus enhances release of matrix protein. J. Virol. 2009, 83:12139-12150.
23. Niwa H., Yamamura K., Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991, 108:193-200.
24. Ogino M., Ebihara H., Lee B.H., Araki K., Lundkvist A., Kawaoka Y., Yoshimatsu K., Arikawa J. Use of vesicular stomatitis virus pseudotypes bearing hantaan or seoul virus envelope proteins in a rapid and safe neutralization test. Clin. Diagn. Lab. Immunol. 2003, 10:154-160.
25. Okuma K., Matsuura Y., Tatsuo H., Inagaki Y., Nakamura M., Yamamoto N., Yanagi Y. Analysis of the molecules involved in human T-cell leukaemia virus type 1 entry by a vesicular stomatitis virus pseudotype bearing its envelope glycoproteins. J. Gen. Virol. 2001, 82:821-830.
26. Perez M., Watanabe M., Whitt M.A., de la Torre J.C. N-terminal domain of Borna disease virus G (p56) protein is sufficient for virus receptor recognition and cell entry. J. Virol. 2001, 75:7078-7085.
27. Porotto M., Carta P., Deng Y., Kellogg G.E., Whitt M., Lu M., Mungall B.A., Moscona A. Molecular determinants of antiviral potency of paramyxovirus entry inhibitors. J. Virol. 2007, 81:10567-10574.
28. Publicover J., Ramsburg E., Rose J.K. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. J. Virol. 2005, 79:13231-13238.
29. Robison, C.S., 2001. Assembly and fusion-potentiation domains of the vesicular stomatitis virus glycoprotein and their utility in the development of cell-type-targeted rhabdoviral vectors, Microbiology & Immunology, Vol. Ph.D., University of Tennessee Health Science Center, Memphis, pp. 157.
30. Robison C.S., Whitt M.A. The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly. J. Virol. 2000, 74:2239-2246.
31. Saha M.N., Tanaka A., Jinno-Oue A., Shimizu N., Tamura K., Shinagawa M., Chiba J., Hoshino H. Formation of vesicular stomatitis virus pseudotypes bearing surface proteins of hepatitis B virus. J. Virol. 2005, 79:12566-12574.
32. Schnell M.J., Johnson J.E., Buonocore L., Rose J.K. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection [see comments]. Cell 1997, 90:849-857.
33. Stillman E.A., Rose J.K., Whitt M.A. Replication and amplification of novel vesicular stomatitis virus minigenomes encoding viral structural proteins. J. Virol. 1995, 69:2946-2953.
34. Symons J.A., Alcami A., Smith G.L. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 1995, 81:551-560.
35. Takada A., Robison C., Goto H., Sanchez A., Murti K.G., Whitt M.A., Kawaoka Y. A novel system for functional analysis of Ebola virus glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:14764-14769.
36. Tamura K., Oue A., Tanaka A., Shimizu N., Takagi H., Kato N., Morikawa A., Hoshino H. Efficient formation of vesicular stomatitis virus pseudotypes bearing the native forms of hepatitis C virus envelope proteins detected after sonication. Microbes Infect. 2005, 7:29-40.
37. Tatsuo H., Okuma K., Tanaka K., Ono N., Minagawa H., Takade A., Matsuura Y., Yanagi Y. Virus entry is a major determinant of cell tropism of Edmonston and wild-type strains of measles virus as revealed by vesicular stomatitis virus pseudotypes bearing their envelope proteins. J. Virol. 2000, 74:4139-4145.
38. Tatsuo H., Ono N., Tanaka K., Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000, 406:893-897.
39. Weiss R.A., Boettiger D., Murphy H.M. Pseudotypes of avian sarcoma viruses with the envelope properties of vesicular stomatitis virus. Virology 1977, 76:808-825.
40. Witte O.N., Baltimore D. Mechanism of formation of pseudotypes between vesicular stomatitis virus and murine leukemia virus. Cell 1977, 11:505-511.
41. Zavada J., Rosenbergova M. Phenotypic mixing of vesicular stomatitis virus with fowl plaque virus. Acta Virol. 1972, 16:103-114.